RT Journal Article
SR Electronic
T1 Causal associations between COVID-19 and Atrial Fibrillation: A bidirectional Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20174417
DO 10.1101/2020.08.13.20174417
A1 Xiaoyu Zhang
A1 Biyan Wang
A1 Di Liu
A1 Jinxia Zhang
A1 Qiuyue Tian
A1 Xiaoni Meng
A1 Jie Zhang
A1 Haifeng Hou
A1 Manshu Song
A1 Wei Wang
A1 Youxin Wang
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.08.13.20174417.abstract
AB Background Observational studies showed that coronavirus disease 2019 (COVID-19) attacks universally and its most menacing progression uniquely endangers the elderly with cardiovascular disease (CVD). Whether COVID-19 is causally related to increasing susceptibility and severity of atrial fibrillation (AF), the main form of CVD, remains still unknown.Methods The study aims to investigate the bidirectional causal relations of COVID-19 with AF using two-sample Mendelian randomization (MR) analysis.Results MR evidence suggested genetically predicted severe COVID-19 was significantly associated with higher risk of AF (odds ratio [OR], 1.041; 95% confidence interval (CI), 1.007-1.076; P = 0.017), while genetically predicted AF was not causally associated with severe COVID-19 (OR, 0.831; 95% CI, 1.619-1.115; P=0.217). There was limited evidence to support association of genetically proxied COVID-19 with risk of AF (OR, 1.051; 95% CI, 0.991-1.114; P=0.097), and vice versa (OR, 0.163; 95% CI, 0.004-6.790; P=0.341). MR-Egger indicated no evidence of pleiotropic bias.Conclusion Overall, severe COVID-19 may causally affect AF through independent biological pathway. Survivors from severe COVID-19 might be of high risk of AF in the future.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe use Genome-wide association studies (GWAS) data from online.Funding StatementThe study was supported by grants from the China-Australian Collaborative Grant (NSFC 81561128020-NHMRC APP1112767).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article and its supplementary information files.